Tirzepatide is a prescription medication approved by the FDA for the treatment of type 2 diabetes mellitus (marketed as Mounjaro) and chronic weight management in adults with obesity or overweight with weight-related comorbidities (marketed as Zepbound)
Laothamteep N, Kawano H, Vejarano F, Suzuki-Minakuchi C, Shintani M, Nojiri H, Pinyakong O
Landmark trials and real-world data consistently demonstrate 510% average weight loss at standard maintenance doses (0.41.0 mg weekly)
That delay affects how other oral medications are absorbed, including phentermine
10.1016/j.jtbi.2003.08.001
This is only a limited summary of general information about the medicines uses from the patient education materials and is not intended to be comprehensive